

**Anti-PTPRC / CD45 Reference Antibody (Novartis patent anti-CD45)
Recombinant Antibody
Catalog # APR10026****Specification**

Anti-PTPRC / CD45 Reference Antibody (Novartis patent anti-CD45) - Product Information

Application	FC, Kinetics, Animal Model
Primary Accession	P08575
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	150 KDa

Anti-PTPRC / CD45 Reference Antibody (Novartis patent anti-CD45) - Additional Information**Target/Specificity**

PTPRC / CD45

Endotoxin

< 0.001EU/ µg,determined by LAL method.

Conjugation

Unconjugated

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Anti-PTPRC / CD45 Reference Antibody (Novartis patent anti-CD45) - Protein Information**Name** PTPRC ([HGNC:9666](#))**Synonyms** CD45**Function**

Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor (PubMed:35767951). Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity (By similarity). Interacts with CLEC10A at antigen presenting cell-T cell contact; CLEC10A on immature dendritic cells recognizes Tn antigen- carrying PTPRC/CD45 receptor on effector T cells and modulates T cell activation threshold to limit autoreactivity.

Cellular Location

Cell membrane; Single-pass type I membrane protein. Membrane raft. Synapse. Note=Colocalized with DPP4 in membrane rafts.

Tissue Location


Isoform 1: Detected in thymocytes. Isoform 2: Detected in thymocytes. Isoform 3: Detected in thymocytes. Isoform 4: Not detected in thymocytes. Isoform 5: Detected in thymocytes. Isoform 6: Not detected in thymocytes. Isoform 7: Detected in thymocytes Isoform 8: Not detected in thymocytes.

Anti-PTPRC / CD45 Reference Antibody (Novartis patent anti-CD45) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


Anti-PTPRC / CD45 Reference Antibody (Novartis patent anti-CD45) - Images



Anti-PTPRC / CD45 Reference Antibody (Novartis patent anti-CD45) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-PTPRC / CD45 Reference Antibody (Novartis patent anti-CD45) is more than 95%, determined by SEC-HPLC.



Immobilized human IL-18 His at 4 µg/mL can bind Anti-PTPRC / CD45 Reference Antibody (Novartis patent anti-CD45) $EC_{50}=0.00604$ µg/mL.